Prevention of disease Archives - Page 3 of 4

exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India

Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio.

From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.

Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

2021

M72/AS01e

Hypothetical vaccines, M72/AS01e

Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.

Estimating the epidemiologic impact of new TB vaccines in high-burden settings

2022-2027

Ongoing

This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.

Estimating the epidemiologic impact of new TB vaccines in the U.S.

2022-2024

Ongoing

This is a study funded by the American Lung Association which will explore the potential impact of targeted implementation of a prevention of disease vaccine in a low TB burden country, the U.S.A.

Preferred product characteristics for new tuberculosis vaccine

2018

The document presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy. Priorities are for a vaccine to be administered to adolescents and adults for prevention of pulmonary tuberculosis and reduction of transmission, and for a pediatric vaccine with improved safety and efficacy as compared to BCG.

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.

Acceptability and effect on public and cost-effectiveness impact